However, PD-1/PD-L1 inhibitor monotherapy has shown limited efficacy in SCLC compared with NSCLC, potentially due to the low presence of tumor-infiltrating lymphocytes (TILs) and the immunosuppressive phenotype of the SCLC microenvironment [43]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.